J. Goldman & CO LP Jounce Therapeutics, Inc. Transaction History

J. Goldman & CO LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 14, 2018	SELL	$7.27 - $21.88 $175,352 - $527,745	-24,120 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$13.4 - $28.4 $346,792 - $734,992	-25,880 Reduced 51.76%	24,120 $539,000
Q4 2017 Feb 16, 2018	BUY	$12.52 - $17.82 $626,000 - $891,000	50,000	50,000 $638,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.